News >

Olaparib Approved in Europe for BRCA+ Breast Cancer

Gina Columbus
Published: Wednesday, Apr 10, 2019

Dave Fredrickson

Dave Fredrickson

The European Commission has approved olaparib (Lynparza) for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication